# Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

> **NCT00014443** · PHASE2 · TERMINATED · sponsor: **Rush University Medical Center** · enrollment: 5 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** thalidomide
- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00014443
- **Lead sponsor:** Rush University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-08
- **Primary completion:** 2003-08
- **Final completion:** 2003-12
- **Target enrollment:** 5 (ESTIMATED)
- **Why stopped:** Poor enrollment
- **Last updated:** 2023-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00014443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00014443, "Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00014443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*